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The fact that alcohol is an addictive drug has been known to
man for millennia.  Alcohol abuse/dependence is the most
common substance-related disorder.1 A drug can be defined as
a substance that produces tolerance (increasingly large
amounts are needed to produce the same effect) and
withdrawal (psychological and physical distress develop after
substance use ceases).  The addicted person suffers both a
craving for the sensation of intoxication, and the phenomenon
of physical dependence (tolerance and withdrawal).  Alcohol is
such a substance.
A not-so-silent epidemic?
Approximately 50% of people can drink alcohol socially
without sustaining any harmful bio-psycho-social effects. If
you study this 50%, it becomes clear that they drink relatively
small amounts and infrequently. The flip side of this statistic
implies that 50% of those who drink are in danger of suffering
some bio-psycho-social loss.  Epidemiological studies of
alcohol dependence are difficult for obvious reasons.  Five to
ten per cent of people worldwide fulfil the criteria for alcohol
dependence during a lifetime.1 Alcoholism therefore represents
an enormous psychosocial dilemma in our community.  It
affects not only individuals, but also their families and the
whole of society.  Consider the burden of fetal alcohol
syndrome, broken families, unemployment, violence and the
enormous medical costs to society. The medical community
frequently avoids dealing with, or ignores this acquired
dependency disorder.  Note that no person would deliberately
set out to become addicted to alcohol.  Even though alcoholics
may vehemently deny that they are dependent, they are still
painfully aware of their condition.  It is extremely important
that the therapist should recognise this disease, acknowledge it,
and actively treat it, since it is eminently treatable.
There are tips that can help people to avoid intoxication:
• Consume no more than one drink (e.g. one 340 ml beer or
equivalent) per hour 
• Never drink on an empty stomach 
• Stop at two, definitely three drinks 
• Pour your own drinks 
• During protracted dinners or functions, drink a glass of
water between drinks 
• Refuse to drive after three drinks 
• Get into the habit of designating a non-drinking driver or
take a taxi.
It does run in the family
People who are more vulnerable to developing alcohol
dependence include:
• People who start to drink at an early age 
• Those who claim to be able to ‘handle’ their liquor 
• Persons who regularly become intoxicated (more than three
drinks, three times a week or more) 
• ‘Bingers’ (those who experience recurring bouts of
uncontrolled drinking behaviour) 
• Persons with a strong family history of alcohol dependence.  
A simple way to test for the presence of dependence is by
means of the following four questions from the  CAGE
questionnaire:  
• Have you ever felt you ought to Cut down?
• Have people Annoyed you by criticising your drinking?
• Have you ever felt Guilty about your drinking?
• Have you ever taken an Eye-opener?
An affirmative response to any of these questions indicates
an underlying alcohol problem.  In clinical practice, when the
diagnosis is made, it should be communicated to the patient,
always with the message that help is at hand and that the
disorder can be treated successfully.  Why?  Nobody
deliberately sets out to become addicted to alcohol.  This fact
should be emphasised at the start in order to build on the
motivation of the patient to enter into treatment.
Why do people become alcohol
dependent?
Alcohol is a drug (as evidenced by the development of
tolerance and withdrawal symptoms). People drink for the
physical and psychological effects it has on them.  Alcohol
stabilises the mood, alleviates tension, and reduces tiredness,
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anger, shyness, frustration and the effects of the daily setbacks
and disappointments of life.  Alcohol offers temporary escape
from all of these.  It calms people down, helps them to forget,
and produces short-lived relief.  Herein, however, lies the great
danger — it is precisely because alcohol has such an effect on
one's life that the habit of using alcohol so easily becomes
repetitive.  Over time, it develops into a pattern, a lifestyle, and
an unhealthy crutch on which to lean. There are stressors that
every individual in our society must face, plus there may be
very personal stressors.  In fact when one thinks about it there
are enough stressors and therefore reasons around for
everybody to ‘use’ alcohol as an escape.  The fact that it is
'normal' to drink in our society strengthens the drinking
behaviour indulged in to relieve stress.  Alcohol dependence
may also result from a genetic predisposition since it plainly
occurs in certain families.3 Persons in whom genetic factors are
operative are typically male, have begun to drink large
amounts of alcohol at an early age, have a clear family history
of alcoholism and have often manifested antisocial tendencies
in their adolescent years. Even if there is a genetic
predisposition, it is important to remember that alcohol
dependence is ultimately an acquired condition.  A young
person with a clear family history of alcoholism ought to be
extra vigilant regarding the use of alcohol.  It is old news that
people who boast that they can ‘take’ their drink are actually
the ones who eventually develop dependence.  
Once the patient is dependent, it becomes very difficult to
‘just stop’, as society would like the addict to do. The patient
has become dependent on the ‘escape’ into alcohol intoxication,
afraid of the unknown sober lifestyle, afraid of possible
withdrawal symptoms, unable to admit to his/her own
‘weakness’ or loss of control.  He/she escapes the problem of
addiction yet again by intoxication, becoming trapped within
his/her illness. Once trapped within his/her addiction the only
way to keep the drinking behaviour going is by means of
empty promises of sobriety, at times angry threats, denial,
rationalisation, projection, minimalisation and
intellectualisation.  The therapist would consider the above
defence mechanisms as signifying poor or no motivation.
Therapists become disillusioned and so frequently ‘turn a blind
eye’ to the mood of the patient.
Treatment
Although important, primary prevention and the promotion of
healthy drinking habits will not be discussed here.
Treatment has two components: one, the proper management
of alcohol withdrawal, and two, rehabilitation as an
out/inpatient.  Alcohol problems in practice need to be
detected and confronted early on.  Confrontation means: ‘I care
about you and that is why I am confronting you with the facts.’
The doctor must relate any signs and symptoms (e.g. gastritis)
to the cause (i.e. alcohol), and offer assistance.  Follow this with
further questioning in an empathic and accepting way, always
furnishing the patient with facts, and the way forward. 
Patients often regard themselves as victims of external
circumstances, and frequently seem to be manipulative.  Real
(internal) motivation to maintain sobriety comes only after
treatment.  Psycho-education is extremely important.  Get the
patient to think about the factors standing in his/her way of
sobriety, possible results of continued drinking and positive
changes that might occur if he/she were to abstain. Treatment
is at hand and has proved in many cases to be successful.  If a
doctor were to confront a patient persistently, honestly and
empathically, provide psycho-education, and offer assistance,
he or she should eventually reach a breakthrough in the
treatment of the alcohol-dependent patient.  Determine
whether the patient requires inpatient or outpatient
detoxification.  Uncomplicated detoxification can be performed
on an outpatient basis, but complicated withdrawal should be
carried out in a hospital. A long-acting benzodiazepine such as
diazepam 5 mg two to three times a day for 5 days should be
prescribed.  Always add thiamine 100 mg  twice daily for 10
days. Because alcohol has a short half-life the patient may use
up to 30 mg of diazepam per 24 hours early in withdrawal and
taper this over the remaining days. If the patient has a history
of withdrawal delirium (delirium tremens or DTs) or is
compromised by physical disorders, hospitalise and treat
accordingly.  Diazepam should not become a substitute for
alcohol.  Carbamazapine may replace diazepam for the
detoxification process, but diazepam is inexpensive and readily
available.  If after detoxification the patient is unable to
maintain the sober lifestyle, not mere sobriety, he/she should
be referred for in/outpatient treatment.
It is very important that you make an effort to motivate the
patient to agree to further treatment.  Provide the patient with
positive feedback that the first phase of successful restoration
to health has been achieved, but that the therapeutic process is
only now ready to begin.  Initially, one can also make use of
family, friends, the employer and other support networks to
‘motivate’ the patient to seek treatment.
The possible alternatives to further rehabilitation include a
short (4 - 6-week) inpatient rehabilitation programme, an
outpatient rehabilitation programme, community-based self-
help programmes (e.g. Alcoholics Anonymous) and
community-based self-help programmes for family members of
addicts.  These are voluntary options, and their outcomes
depend largely on the doctor’s initial success in motivating the
patient.  Inpatient rehabilitation is the treatment of choice for
those patients who have forgotten what it is like to be sober,
and who have demonstrated that they cannot remain sober in
the community.  Outpatient therapy in the form of network
therapy can be very successful.  Outpatient network therapy, as
described by Galanter,4 is based on a network that includes the
therapist, the addict and a close significant other or supporting
person.  In this manner, therapy occurring in the consulting
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room can be  monitored continuously outside.  The dependent
person becomes ‘connected’ to an outside support system,
thereby preventing isolation.  Once the patient has completed
the rehabilitation programme, follow-up is of the utmost
importance.  Severe and protracted relapses can be prevented
through regular contact with the doctor, encouragement,
positive reinforcement, and assistance with obstacles in the
path of sobriety and the prompt management of relapse.  
As an adjunct to the rehabilitation process, pharmacotherapy
for alcoholism is becoming a reality.5 New exciting
pharmacotherapeutic possibilities, challenging the
neurobiological origin of addiction as well as the neuronal
changes brought on by the addiction process, have become a
reality in contemporary medicine.  Old and new
pharmacotherapy in the field of addiction can make positive
contributions to rehabilitation programmes and should always
go hand in hand.  Pharmacotherapy for alcohol addiction after
detoxification includes the following:  
Disulfiram (Antabuse 400 mg), dosage 200 mg/day 
(1/2 tablet): During the first stage of sobriety, patients often still
feel very unsure of themselves and may therefore readily
accept disulfiram if it is offered to them.  Disulfiram can be
effective if used according to the following procedure:  the
patient takes disulfiram first thing in the morning, while
motivation for abstinence is still high.  Now the patient knows
that he or she will certainly not be able to drink, because
alcohol would cause severe physical discomfort, such as
palpitations, headaches, abdominal cramps, nausea, dizziness
and flushing for 30 - 60 minutes.  Disulfiram blocks
acetaldehyde dehydrogenase, causing acetaldehyde, which
produces physical discomfort, to accumulate.  Patients must be
thoroughly instructed regarding the mode of action of
disulfiram, and must use it of their own free will.  Disulfiram
remains an external motivator.  It should not be given  without
informed consent from the patient. This form of aversive
therapy can be very effective, but only when combined with an
ongoing good doctor-patient relationship.
Naltrexone (ReVia 50 mg): Naltrexone is an opioid
antagonist. It may be useful to administer an opiate antagonist
while the person is still drinking.6 The opiate antagonist blocks
dopamine/endogenous opiate positive reinforcement, with
resulting decrease in drinking behaviour.  If intoxication loses
its ‘kick’ or secondary ‘endorfine’ effect, the person should
drink less.  This may pave the way towards the decision to
stop drinking, and sobriety.  Naltrexone can only be successful
as an adjunct to psychotherapy within a treatment programme.
In South Africa ReVia is registered for the treatment of opioid
addiction.  On day one use 25 mg naltrexone.  If there are no
signs of opiate withdrawal then use naltrexone 50 mg/day
(average dose 50 - 100 mg/day).  It can also be prescribed as
100 mg every second day.   Contraindications for use are opiate
dependence, liver failure, hepatitis, and opiate analgesic/anti-
cough use.   
Acamprosate (Besobrial 333 mg): The process of alcohol
addiction can be explained by a slow neuro-adaptation. These
changes are protracted and sometimes permanent.  Long-term
alcohol abuse upregulates NMDA (N-methyl-D-aspartate)
receptors in the glutamate system and downregulates GABA
(gamma-aminobutyric acid) receptors.  This leads to ongoing
craving (return of old drinking stimuli).  Acamprosate, with a
chemical structure similar to that of amino-acid neuro-
mediators, may repair the amine system, thus alleviating
craving and helping the patient to maintain sobriety.7 It would
therefore make sense that once the addict achieves sobriety,
he/she could be helped by curbing the ongoing craving with
the use of acamprosate.  It must be stressed that acamprosate
can only be of benefit within an ongoing rehabilitation
programme between therapist and patient.  Acamprosate 333
mg two tablets three times a day should be prescribed for 6 - 12
months.  The drug must be swallowed whole, and is well
tolerated and safe.  It should not be given to patients with
severe liver disease or impaired renal function, and it has not
been proved safe during pregnancy and breast-feeding
Besobrial has proved itself to be an effective drug in
combination with ongoing psychotherapy for alcohol
dependence within the doctor-patient relationship.  
Anti-epileptic drugs. Anti-epileptic drugs have been used in
the treatment of alcohol withdrawal. In theory these drugs
could 'substitute' for alcohol and reduce the symptoms of
ongoing craving. Carbamazepine, gabapentin, valproic acid
and now topiramate have been shown to reduce alcohol
consumption.  Topiramate, like alcohol, inhibits excitation at
the glutamate level and enhances GABA-nergic activity, thus
mimicking the action of alcohol, while not resulting in abuse.8
The use of anti-epileptic drugs for the treatment of alcohol
addiction is not standard practice at this time.  
For too long society and therapists have looked the other
way.  Addicts are trapped within their illness.  Their denial
only reiterates their hopelessness within this illness.  We
should challenge this illness and use all the effective ‘tools’ of
treatment available to us, be this early confrontation, the kind-
but-firm approach, always promoting the success and
availability of treatment, making appointments, and following
through on therapy with compassion and energy.  
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